Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes

Kristen Sullivan, Barbara S. Doumouras, Bernadet T. Santema, Mary Norine Walsh, Pamela S. Douglas, Adriaan A. Voors, Harriette G. C. Van Spall*

*Bijbehorende auteur voor dit werk

Onderzoeksoutputpeer review

41 Citaten (Scopus)
154 Downloads (Pure)


Heart failure (HF) is a leading cause of hospitalisation, morbidity, and mortality in Canada. There are sex-specific differences in the etiology, epidemiology, comorbidities, treatment response, and treatment adverse effects that have implications on outcomes in HF. Sex-specific analyses of some HF trials indicate that optimal doses of drug therapies and benefit of device therapies may differ between male and female patients, but the trials were not designed to test sex differences. The under-representation of female participants in HF randomised controlled trials (RCTs) is a major limitation in assessing the sex-specific efficacy and safety of treatments. To ensure that female patients receive safe and effective HF therapies, RCTs should include participants proportionate to the sex-specific distribution of disease. This review outlines the sex-specific differences in HF phenotype and treatment response, and highlights disparities in services and gaps in knowledge that merit further investigation.

Originele taal-2English
Pagina's (van-tot)560-571
Aantal pagina's12
TijdschriftCanadian Journal of Cardiology
Nummer van het tijdschrift4
StatusPublished - apr.-2021


Duik in de onderzoeksthema's van 'Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes'. Samen vormen ze een unieke vingerafdruk.

Citeer dit